Truist Securities Reiterates Buy Rating on Ultragenyx Pharma (RARE)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Leerink on Ultragenyx Pharma (RARE): 'DTX401 Rolling BLA Submitted, Setting Up Launch for Underappreciated Program'
December 31, 2025 9:23 AM ESTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $70.00 price target on Ultragenyx Pharma (NASDAQ: RARE).
The analyst comments "In line with expectations, Ultragenyx (RARE, OP) completed the rolling submission of DTX401's BLA, setting up a potential launch in 2026; we continue to think this is an underappreciated asset within the company, which may begin to get more... More
Ultragenyx Pharma (RARE) PT Lowered to $70 at Leerink Partners
December 29, 2025 3:27 PM ESTLeerink Partners analyst Joseph Schwartz lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $70.00 (from $80.00) while maintaining a Outperform rating.
... MoreUltragenyx Pharma (RARE) PT Lowered to $47 at Baird
December 29, 2025 12:48 PM ESTBaird analyst Joel Beatty lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $47.00 (from $72.00) while maintaining a Outperform rating.
The analyst comments "Negative on clinical trial update. This morning, Ultragenyx announced that neither the ORBIT nor COSMIC study of setrusumab produced a statistically... More
William Blair Reiterates Outperform Rating on Ultragenyx Pharma (RARE)
December 29, 2025 12:04 PM ESTWilliam Blair analyst Sami Corwin reiterated an Outperform rating and {REMOVEPT} price target on Ultragenyx Pharma (NASDAQ: RARE).
The analyst comments "Stock thoughts: W e are disappointed and surprised by today s news given setrusumab s ef ficacy in the Phase II portion of the Orbit study and the increased enrollment of patients with severe disease subtypes (type III/IV) in the Phase III study ,... More
